Peptidream
PeptiDream Inc., a leading biotechnology company headquartered in Japan, specialises in the discovery and development of peptide-based therapeutics. Founded in 2006, PeptiDream has established itself as a pioneer in the field of peptide drug design, leveraging its proprietary Peptide Discovery Platform System (PDPS) to create unique peptide compounds for various therapeutic applications. With a strong presence in Japan and expanding operations in North America and Europe, PeptiDream focuses on oncology, metabolic diseases, and central nervous system disorders. The company has achieved significant milestones, including collaborations with major pharmaceutical firms, which underscore its market position as a key player in peptide therapeutics. PeptiDream's innovative approach and commitment to advancing peptide-based solutions set it apart in the competitive biotechnology landscape.
DitchCarbon Score
How does Peptidream's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Peptidream's score of 7 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Peptidream's reported carbon emissions
In 2020, PeptiDream reported total carbon emissions of approximately 246,420 kg CO2e, comprising 9,210 kg CO2e from Scope 1, 9,210 kg CO2e from Scope 2, and a significant 236,000 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions included about 35,000 kg CO2e from employee commuting and approximately 201,000 kg CO2e from fuel and energy-related activities. In 2021, the company achieved a reduction in its Scope 1 and Scope 2 emissions, reporting a total of 7,720 kg CO2e for each scope, indicating a commitment to lowering its direct emissions. However, in 2022, PeptiDream reported no emissions for Scope 1 and Scope 2, suggesting a significant shift in their operational practices or reporting methods. PeptiDream has committed to near-term reduction targets, although specific numerical targets have not been disclosed. The company has not yet committed to a net-zero target. Their ongoing efforts reflect a proactive approach to managing carbon emissions within the pharmaceuticals, biotechnology, and life sciences sector, based in Japan.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 9,210 | 0,000 |
| Scope 2 | 9,210 | 0,000 |
| Scope 3 | 236,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Peptidream is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
